Vicarius Pharma

Vicarius Pharma AG was a Swiss-based pharmaceutical services company founded in 2016 that specialized in providing go-to-market strategies for U.S.-based biopharmaceutical companies looking to commercialize products in Europe. The company focused on specialty, rare/orphan, and hospital products, offering a partnership model where it acted as the innovator's go-to-market organization, managing regulatory, pricing, and commercial strategies while absorbing launch costs. Led by former Biogen and Elan executive Hans Peter Hasler, the firm aimed to allow U.S. companies to retain control of their assets while expanding internationally. Despite raising $21.8 million in Series A funding in 2017, the company entered bankruptcy and liquidation in July 2020.